Skip to main content

IncyteCARES is a program for residents
of the United States and Puerto Rico.

For the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 2 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.

For the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

IncyteCARES for OPZELURA
Patient Assistance Program

Illustration of patient and caregiver riding bikes
Rx with helping hand icon

IncyteCARES for OPZELURA Patient Assistance Program

The IncyteCARES for OPZELURA Patient Assistance Program provides OPZELURA at no cost to eligible patients in need.* You may be eligible if you are uninsured or have Medicare Part D coverage.

You are considered uninsured if you have no prescription insurance. If you have medical insurance, it may not cover OPZELURA. If you are unsure about your coverage, contact your doctor or health plan.

*Terms and Conditions apply. Terms of this Program may change at any time.

The IncyteCARES for OPZELURA Patient Assistance Program provides OPZELURA at no cost to eligible patients in need.* You may be eligible if you are uninsured or have Medicare Part D coverage.

You are considered uninsured if you have no prescription insurance. If you have medical insurance, it may not cover OPZELURA. If you are unsure about your coverage, contact your doctor or health plan.

*Terms and Conditions apply. Terms of this Program may change at any time.

To be eligible for the Patient Assistance Program, you must:

  • Be uninsured or have Medicare Part D coverage and cannot afford your copay
  • Have a valid prescription for OPZELURA for mild to moderate eczema (atopic dermatitis) or nonsegmental vitiligo
  • Have an adjusted annual household income that is less than or equal to 400% of the Federal Poverty Level

Additional eligibility criteria if you have Medicare Part D coverage:

  • Have a prior authorization (PA) submitted to your insurance plan by your doctor. If the PA is denied, an appeal must be submitted
  • You must be enrolled in a Medicare Part D prescription insurance plan and have expressed and documented an inability to afford your out-of-pocket cost
  • You must not be a beneficiary of any of these government insurance or healthcare programs, including, but not limited to:
  • Medicaid
  • Medicare Part D Low-Income Subsidy (LIS) program
  • Veterans Affairs (VA)
  • Department of Defense (DoD)
  • TRICARE
  • Any State Pharmaceutical Assistance Program (SPAP)

If you have LIS and your Medicare Part D plan denies coverage for OPZELURA through a PA and appeal, you may be eligible for the Patient Assistance Program.

The table below shows who might qualify for the Patient Assistance Program

If this many people live
in your household:

You may qualify if your full-year income
before taxes is less than or equal to:

1 person

$63,840

2 people

$86,560

3 people

$109,280

4 people

$132,000

5 people

$154,720

If you live in Alaska or Hawaii or have a household with more than 5 members, please call IncyteCARES for OPZELURA at 1-800-583-6964 to see if you may qualify.

Income levels are subject to change on an annual basis; the numbers in this table are based on the 2026 Federal Poverty Level Guidelines.

How it works

Form Icon

GETTING
STARTED

Your doctor will need to complete and submit the Patient Assistance Program Enrollment Form for OPZELURA. You will need to sign the form and provide proof of your household income.

Your doctor will need to complete and submit the Patient Assistance Program Enrollment Form for OPZELURA. You will need to sign the form and provide proof of your household income.

Dollar sign icon

PROVIDING PROOF
OF INCOME

To qualify for the Program, IncyteCARES will need to verify your household income. You can either:

Have IncyteCARES verify your income electronically by signing the Electronic Income Verification section on the enrollment form

OR

Submit one of the following, your most recent:

  • Federal income tax return (Form 1040)
  • W-2 earnings statement from your employer
  • Social Security Benefit Verification Letter

Submit the required documentation to your doctor to fax with your Program application or mail it separately to IncyteCARES for OPZELURA PAP, 6000 Park Lane, Pittsburgh, PA 15275.

To qualify for the Program, IncyteCARES will need to verify your household income. You can either:

Have IncyteCARES verify your income electronically by signing the Electronic Income Verification section on the enrollment form

OR

Submit one of the following, your most recent:

  • Federal income tax return (Form 1040)
  • W-2 earnings statement from your employer
  • Social Security Benefit Verification Letter

Submit the required documentation to your doctor to fax with your Program application or mail it separately to IncyteCARES for OPZELURA PAP, 6000 Park Lane, Pittsburgh, PA 15275.

RX Delivery Truck Icon

GETTING YOUR
MEDICATION

If you are approved for the Patient Assistance Program, OPZELURA will be shipped to you from the designated Program pharmacy.

  • Uninsured: You are enrolled up to 12 months, and after that, you must apply to be re-enrolled
  • Medicare Part D coverage: You are enrolled for the calendar year and must re-enroll each year

If you are approved for the Patient Assistance Program, OPZELURA will be shipped to you from the designated Program pharmacy.

  • Uninsured: You are enrolled up to 12 months, and after that, you must apply to be re-enrolled
  • Medicare Part D coverage: You are enrolled for the calendar year and must re-enroll each year
RX Tube Icon

PRESCRIPTION
REFILLS

You must call IncyteCARES for OPZELURA at 1-800-583-6964 to refill your prescription
for OPZELURA.

You must call IncyteCARES for OPZELURA at 1-800-583-6964 to refill your prescription
for OPZELURA.

Cell phone icon

Questions?
Call IncyteCARES for OPZELURA at
1-800-583-6964,
Monday through Friday, 8 AM–8 PM ET.

Opzelura On Trac™ logo

Support along your treatment journey

Understand how to use OPZELURA, what to expect as you get started, and access additional tools and resources.

Learn More

INDICATION AND USAGE

OPZELURA is a prescription medicine used on the skin (topical) for:

  • short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 2 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended
  • the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors, which are medicines that affect your immune system and can lower your ability to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while using OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes) and major cardiovascular events: Increased risk of death and major cardiovascular events (eg, heart attack or stroke) has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking JAK inhibitors by mouth, especially current or past smokers.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. People taking JAK inhibitors by mouth have reported lymphoma and other cancers and are at higher risk of certain cancers including lymphoma and lung cancer, especially if they have ever smoked. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment. Limit the amount of time you spend in the sun, wear protective clothing and use a broad-spectrum sunscreen.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. DVT and PE have happened more often in people taking JAK inhibitors by mouth who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia, lymphopenia, leukopenia). Your healthcare provider may do a blood test to check your blood cell counts during your treatment and may stop your treatment if signs or symptoms of low blood cell counts happen.

Potential risks from Janus kinase (JAK) inhibition: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides. Low blood sugar in people with diabetes has happened after taking JAK inhibitors by mouth.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have or have had hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common
  • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had a heart attack, other heart problems, or a stroke
  • have had blood clots in the veins of your legs or lungs in the past
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com. This registry is intended to collect information about the health of you and your baby
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack, blood clot, or stroke while using OPZELURA, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
    • swelling, pain, or tenderness in one or both legs
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count or decrease in a type of white blood cell (neutropenia) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), runny nose (rhinorrhea), upper respiratory tract infection, COVID-19, fever, and pain, irritation, discomfort, or itching at the application site.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

INDICATION AND USAGE

OPZELURA is a prescription medicine used on the skin (topical) for:

  • short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 2 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended
  • the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older

The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION

OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors, which are medicines that affect your immune system and can lower your ability to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while using OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death due to any reason (all causes) and major cardiovascular events: Increased risk of death and major cardiovascular events (eg, heart attack or stroke) has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking JAK inhibitors by mouth, especially current or past smokers.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. People taking JAK inhibitors by mouth have reported lymphoma and other cancers and are at higher risk of certain cancers including lymphoma and lung cancer, especially if they have ever smoked. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment. Limit the amount of time you spend in the sun, wear protective clothing and use a broad-spectrum sunscreen.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. DVT and PE have happened more often in people taking JAK inhibitors by mouth who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia, lymphopenia, leukopenia). Your healthcare provider may do a blood test to check your blood cell counts during your treatment and may stop your treatment if signs or symptoms of low blood cell counts happen.

Potential risks from Janus kinase (JAK) inhibition: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides. Low blood sugar in people with diabetes has happened after taking JAK inhibitors by mouth.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have or have had hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common
  • think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had a heart attack, other heart problems, or a stroke
  • have had blood clots in the veins of your legs or lungs in the past
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or www.opzelura.pregnancy.incyte.com. This registry is intended to collect information about the health of you and your baby
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack, blood clot, or stroke while using OPZELURA, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
    • swelling, pain, or tenderness in one or both legs
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count or decrease in a type of white blood cell (neutropenia) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), runny nose (rhinorrhea), upper respiratory tract infection, COVID-19, fever, and pain, irritation, discomfort, or itching at the application site.

The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.